All Insight, Analysis and Views

ViewPoints: A Viking raid on Madrigal solidifies THR as the hottest new thing in NASH

Ref: ViewPoints Desk

Tags: ViewPoints Viking Therapeutics Madrigal Pharmaceuticals Nonalcoholic steatohepatitis Clinical Research (R&D) Regulatory Affairs AASLD VK2809 MGL-3196

ViewPoints: An FDA go-ahead for Mersana could still mean trouble

Ref: ViewPoints Desk

Tags: ViewPoints Mersana Therapeutics United States Breast Cancer Ovarian Cancer FDA Regulatory Affairs XMT-1522 XMT-1536

ViewPoints: Teva still has everything to prove with Ajovy product launch

Ref: ViewPoints Desk

Tags: ViewPoints Teva Amgen Novartis Lilly Alder United States Migraine FDA Marketing & Sales Regulatory Affairs Ajovy Aimovig galcanezumab eptinezumab

ViewPoints: Loxo dinged by greater transparency

Ref: ViewPoints Desk

Tags: ViewPoints Loxo Oncology Bayer Roche FDA Marketing & Sales Medical Affairs Regulatory Affairs larotrectinib entrectinib

ViewPoints: BI 655130 data pip IL-36 as another I&I target on the come up

Ref: ViewPoints Desk

Tags: ViewPoints Boehringer Ingelheim AnaptysBio Psoriasis FDA Clinical Research (R&D)BI 655130 ANB019

ViewPoints: Allogene hopes to put its money where its mouth is with quickstart IPO

Ref: ViewPoints Desk

Tags: ViewPoints Allogene Kite Gilead Novartis Corporate Affairs

ViewPoints: Alnylam feeling effects of yo-yoing sentiment on cardiac safety

Ref: ViewPoints Desk

Tags: ViewPoints Alnylam Ionis Pharmaceuticals Pfizer EMA FDA Marketing & Sales Medical Affairs Regulatory Affairs Onpattro tafamidis Tegsedi

ViewPoints: BMS-986165 appears on track to JAK Celgene’s I&I style

Ref: ViewPoints Desk

Tags: ViewPoints BMS Celgene Nimbus Therapeutics Pfizer Irritable Bowel Syndrome Psoriasis FDA Clinical Research (R&D) Marketing & Sales Medical Affairs BMS-986165 Otezla ozanimod PF-06826647 PF-6700841